174 related articles for article (PubMed ID: 37923991)
1. Prediction of survival and analysis of prognostic factors for hepatocellular carcinoma: a 20-year of imaging diagnosis in Upper Northern Thailand.
Nakharutai N; Chitapanarux I; Traisathit P; Srikummoon P; Pojchamarnwiputh S; Inmutto N; Na Chiangmai W
BMC Cancer; 2023 Nov; 23(1):1063. PubMed ID: 37923991
[TBL] [Abstract][Full Text] [Related]
2. Predictors and Cumulative Frequency of Hepatocellular Carcinoma in High and Intermediate LI-RADS Lesions: A Cohort Study from a Canadian Academic Institution.
Tang ES; Hall G; Yu D; Menard A; Hopman W; Nanji S
Ann Surg Oncol; 2019 Aug; 26(8):2560-2567. PubMed ID: 31025229
[TBL] [Abstract][Full Text] [Related]
3. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
4. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
5. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
[No Abstract] [Full Text] [Related]
6. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
[TBL] [Abstract][Full Text] [Related]
7. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
8. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
[No Abstract] [Full Text] [Related]
9. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of US Surveillance of Hepatocellular Carcinoma in Chronic Hepatitis B: US LI-RADS Visualization Score.
Park MK; Lee DH; Hur BY; Lee HC; Lee YB; Yu SJ; Kim YJ; Yoon JH; Lee JH
Radiology; 2023 Jun; 307(5):e222106. PubMed ID: 37249427
[TBL] [Abstract][Full Text] [Related]
11. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
[TBL] [Abstract][Full Text] [Related]
12. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
[TBL] [Abstract][Full Text] [Related]
15. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
[TBL] [Abstract][Full Text] [Related]
16. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI.
Cha H; Choi JY; Park YN; Han K; Jang M; Kim MJ; Park MS; Rhee H
Eur Radiol; 2023 Feb; 33(2):1364-1377. PubMed ID: 35999373
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
18. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
[TBL] [Abstract][Full Text] [Related]
19. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
20. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
